Every material Form 8-K RELMADA THERAPEUTICS, INC. has filed with the SEC since July 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Relmada Therapeutics disclosed in a Form 8-K that Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026. The filing does not state the reason for the departure or name a successor.
Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026
The filing was dated September 8, 2026 and signed by CEO Sergio Traversa
The filing does not give a reason for the departure or name a replacement
Relmada reported a second-quarter 2026 net loss of $12.9 million, up from $9.9 million a year earlier, as research and development spending rose to $8.4 million from $2.8 million. The loss per share narrowed to $0.11 from $0.30, but the company's weighted average share count grew to 112.4 million from 33.2 million. The company said its $217.7 million in cash and short-term investments is expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.
Net loss of $12.9 million, or $0.11 per share, for the three months ended June 30, 2026, versus $9.9 million, or $0.30 per share, a year earlier
Research and development expense rose to $8.4 million from $2.8 million, mainly due to higher NDV-01 and sepranolone study costs and manufacturing and drug storage costs
Cash, cash equivalents and short-term investments were $217.7 million at June 30, 2026, up from about $93.0 million at December 31, 2025
The company expects to submit the NDV-01 IND and the sepranolone IND by year-end 2026
Relmada Therapeutics announced on July 28, 2026 that it appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer, reporting to CEO Sergio Traversa. He will lead corporate strategy, commercial planning, and business development as the company advances NDV-01 toward late-stage development. The filing does not disclose compensation terms or financial figures for the appointment.
Appointment announced July 28, 2026; Dalmia reports directly to CEO Sergio Traversa
Responsibilities include corporate strategy, commercial planning, and business development
Previously Senior Vice President, Global Head of Portfolio Strategy & Business Development at Ferring Pharmaceuticals, with a 14-year tenure there
The filing does not disclose compensation or other financial terms of the appointment
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RELMADA THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →